These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29116050)

  • 1. Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.
    Jia J; Tang H; Ning Q; Jiang J; Dou X; Zhang M; Zhang S; Shang J; Lu W; Ye Y; Wang X; Li M; Liu J; Bo Q; Tan W;
    Antivir Ther; 2018; 23(3):201-209. PubMed ID: 29116050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.
    Jia J; Shang J; Tang H; Jiang J; Ning Q; Dou X; Zhang S; Zhang M; Han T; Tan D; Zhou X; Chen G; Sheng J; Su Z; Chen H; Dai E; Ye Y; Guo Y; Shen Y; Yuan J; Wei Z; Zhu S;
    Antivir Ther; 2020; 25(6):293-304. PubMed ID: 33090970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
    Kim HJ; Park SK; Yang HJ; Jung YS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Choi KY
    Clin Mol Hepatol; 2016 Sep; 22(3):350-358. PubMed ID: 27729626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
    Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
    Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.
    Hwang JA; Kim KB; Yang MJ; Lim SG; Hwang JC; Cheong JY; Cho SW; Kim SS
    Clin Mol Hepatol; 2015 Jun; 21(2):131-40. PubMed ID: 26157750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.
    Lee KJ; Choe BH; Choe JY; Kim JY; Jeong IS; Kim JW; Yang HR; Chang JY; Kim KM; Moon JS; Ko JS
    J Korean Med Sci; 2018 Feb; 33(8):e63. PubMed ID: 29441755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China: a retrospective study.
    Li W; Wang L; Liu Y; Li Y; Yu S
    Pharmazie; 2018 Apr; 73(4):223-247. PubMed ID: 29609690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
    Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
    J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
    Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
    Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety.
    Lian JS; Zhang XL; Lu YF; Chen JY; Zhang YM; Jia HY; Zhang Z; Yang YD
    Int J Med Sci; 2019; 16(1):17-22. PubMed ID: 30662324
    [No Abstract]   [Full Text] [Related]  

  • 17. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.
    Lee JH; Cho Y; Lee DH; Lee M; Yoo JJ; Choi WM; Cho YY; Lee YB; Yu SJ; Yoon JH; Lee HS; Kim YJ
    Antimicrob Agents Chemother; 2014; 58(3):1730-7. PubMed ID: 24395227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
    Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.